Literature DB >> 17436087

Causes of death in patients with unresectable hepatocellular carcinoma.

O F M Couto1, I Dvorchik, B I Carr.   

Abstract

Most patients with hepatocellular carcinoma (HCC) also have cirrhosis, an independent cause of death. We considered an alternative definition of tumor-related death in patients with HCC and attempted to validate our definition. Two hundred thirty-seven HCC patients were diagnosed, followed, and died over a 12-year period and were evaluated every 2 months, including their last 6 months of life. We defined death by cancer if there was, in the last 6 months of life, a CT scan increase of >25% in the sum of tumor index lesions' cross-sectional areas or new onset of, or increase in, either vascular invasion or metastatic disease (Group 1). Patients with stable cancer were considered to have died from any other cause (Group 2). We found that 135 (57%) patients died from cancer progression (Group 1), whereas 102 (43%) patients did not (Group 2). There was a statistically significant difference between Group 1 and Group 2 patients in percentage with bilobar disease (P = 0.03), more than one tumor (P = 0.01), an increase in AFP (P = 0.04), vascular invasion (P = 0.001), and the presence of metastases (P = 0.01). We conclude that 57% of patients with unresectable HCC died as a direct result of cancer progression, but 43% did not. The latter died from complications of their cirrhosis, including sepsis, GI bleeds, and renal failure.

Entities:  

Mesh:

Year:  2007        PMID: 17436087     DOI: 10.1007/s10620-007-9750-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

3.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 4.  Hepatocellular carcinoma: present status and future prospects.

Authors:  Josep M Llovet; Michel Beaugrand
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

Review 5.  Hepatocellular carcinoma: diagnosis and treatment.

Authors:  Alex S Befeler; Adrian M Di Bisceglie
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

6.  Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients.

Authors:  Brian I Carr
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

7.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

Review 8.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

Review 9.  Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma.

Authors:  M Varela; M Sala; J M Llovet; J Bruix
Journal:  Aliment Pharmacol Ther       Date:  2003-06       Impact factor: 8.171

10.  Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan.

Authors: 
Journal:  Cancer       Date:  1994-11-15       Impact factor: 6.860

View more
  13 in total

1.  Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.

Authors:  Brian I Carr; Petr Pancoska; Robert A Branch
Journal:  Hepatol Int       Date:  2009-12-24       Impact factor: 6.047

2.  Screening for hepatocellular carcinoma by Egyptian physicians.

Authors:  Sahar M Hassany; Ehab F Abdou Moustafa; Mohamed El Taher; Afaf Adel Abdeltwab; Hubert E Blum
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

3.  Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion.

Authors:  Ying Fu; Jun Li; Ming-Xuan Feng; Xiao-Mei Yang; Ya-Hui Wang; Yan-Li Zhang; Wenxin Qin; Qiang Xia; Zhi-Gang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.

Authors:  Brian I Carr; Venkateswarlu Kondragunta; Shama C Buch; Robert A Branch
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

Review 5.  Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.

Authors:  Cindy Neuzillet; Armand de Gramont; Annemilaï Tijeras-Raballand; Louis de Mestier; Jérome Cros; Sandrine Faivre; Eric Raymond
Journal:  Oncotarget       Date:  2014-01-15

Review 6.  Cancer and liver cirrhosis: implications on prognosis and management.

Authors:  Matthias Pinter; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  ESMO Open       Date:  2016-03-17

7.  Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients.

Authors:  Justin Y Tang; Nitin Ohri; Rafi Kabarriti; Santiago Aparo; Jennifer Chuy; Sanjay Goel; Jonathan M Schwartz; Milan Kinkhabwala; Andreas Kaubisch; Chandan Guha
Journal:  Can J Gastroenterol Hepatol       Date:  2018-11-07

8.  Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study.

Authors:  Jihye Lim; Ha Il Kim; Eunju Kim; Jiyoon Kim; Jihyun An; Seheon Chang; Seon-Ok Kim; Han Chu Lee; Yung Sang Lee; Ju Hyun Shim
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

9.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.

Authors:  Tim F Greten; Ghassan K Abou-Alfa; Ann-Lii Cheng; Austin G Duffy; Anthony B El-Khoueiry; Richard S Finn; Peter R Galle; Lipika Goyal; Aiwu Ruth He; Ahmed O Kaseb; Robin Kate Kelley; Riccardo Lencioni; Amaia Lujambio; Donna Mabry Hrones; David J Pinato; Bruno Sangro; Roberto I Troisi; Andrea Wilson Woods; Thomas Yau; Andrew X Zhu; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

10.  A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.

Authors:  Ahmed Omar Kaseb; S Cheenu Kappadath; Sunyoung S Lee; Kanwal Pratap Raghav; Yehia I Mohamed; Lianchun Xiao; Jeffrey S Morris; Chimela Ohaji; Rony Avritscher; Bruno C Odisio; Joshua Kuban; Mohamed E Abdelsalam; Beth Chasen; Khaled M Elsayes; Mohamed Elbanan; Robert A Wolff; James C Yao; Armeen Mahvash
Journal:  J Hepatocell Carcinoma       Date:  2021-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.